The American journal of medicine
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.
To study the efficacy and safety of various dosages of metformin as compared with placebo in patients with type II diabetes mellitus. ⋯ Metformin lowered fasting plasma glucose and HbA1c generally in a dose-related manner. Benefits were observed with as little as 500 mg of metformin; maximal benefits were observed at the upper limits of the recommended daily dosage. All dosages were well tolerated. Metformin appears to be a useful therapeutic option for physicians who wish to titrate drug therapy to achieve target glucose concentrations.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
To compare the therapeutic potential of acarbose, metformin, or placebo as first line treatment in patients with non-insulin-dependent diabetes mellitus (NIDDM). ⋯ Acarbose and metformin are effective drugs for the first line monotherapy of patients with NIDDM. With respect to plasma lipid profile, especially HDL cholesterol, LDL cholesterol and LDL/HDL cholesterol ratio acarbose may be superior to metformin.